<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1916">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468009</url>
  </required_header>
  <id_info>
    <org_study_id>1725</org_study_id>
    <nct_id>NCT04468009</nct_id>
  </id_info>
  <brief_title>Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma</brief_title>
  <official_title>Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Infecciosas Francisco Javier Muniz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Infecciosas Francisco Javier Muniz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to collect convalescent plasma and use it as experimental treatment in
      critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive
      care unit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to use convalescent plasma as experimental treatment in critically ill
      Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
      Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19
      patients on mechanical ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at ICU at 30 days</measure>
    <time_frame>Mortality at 30 days</time_frame>
    <description>Mortality at 30 days of Intensive Care Unit (ICU) admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality at ICU at 90 days</measure>
    <time_frame>Mortality at 90 days</time_frame>
    <description>Mortality at 90 days of ICU admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFA score of study days 1, 3, 5, 7, 14 and 28</measure>
    <time_frame>Study days 1, 3, 5, 7, 14 and 28</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) of study days 1, 3, 5, 7, 14 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for supportive therapy after enrollment</measure>
    <time_frame>Duration of supportive therapy through study completion, an average of 3 months</time_frame>
    <description>Duration (number of days) of supportive therapy (oxygen and ventilation, dialysis, vasopressors) after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lenght of stay in ICU</measure>
    <time_frame>Duration of stay in ICU through study completion, an average of 3 months</time_frame>
    <description>Duration (number of days) of stay in ICU between ICU admission and ICU final discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lenght of mechanical ventilation</measure>
    <time_frame>Duration of mechanical ventilation through study completion, an average of 3 months</time_frame>
    <description>Duration (number of days) of mechanical ventilation between beginning and final liberation from mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lenght of hospitalization</measure>
    <time_frame>Duration of hospitalization through study completion, an average of 3 months</time_frame>
    <description>Duration (number of days) of hospitalization between hospital admission and final hospital discharge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lenght of hospitalization after ICU discharge</measure>
    <time_frame>Duration (number of days) of hospitalization through study completion, an average of 3 months</time_frame>
    <description>Duration (number of days) of hospitalization after ICU discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>Days without ventilation after enrollment</measure>
    <time_frame>Days without ventilation through study completion, an average of 3 months</time_frame>
    <description>Number of days without ventilation after enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>Days without vasopressors after enrollment</measure>
    <time_frame>Days without vasopressors through study completion, an average of 3 months</time_frame>
    <description>Number of days without vasopressors after enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Chest X-ray</measure>
    <time_frame>Changes in Chest X-ray through study completion, an average of 3 months</time_frame>
    <description>Changes in Chest X-ray (unilateral, bilateral, unique, multiple, pleural effusion) after enrollment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>SARS-Associated Coronavirus</condition>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care for Covid-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCC-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with convalescent plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies</description>
    <arm_group_label>PCC-19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years or more.

          -  Patient with Covid-19 confirmed with nuclear acid testing

          -  Critically ill patients with Covid-19 on mechanical ventilation. Potencially
             critically ill patients (with acute respiratory distress syndrome, septic shock and/or
             multiple organ failure) with Covid-19.

          -  Diagnosed with acute respiratory distress syndrome.

          -  Informed consent.

        Exclusion Criteria:

          -  No consent.

          -  Symptoms for a period longer than 20 days.

          -  Not detectable by acid nuclear testing within 48 hours prior to elegibility.

          -  Descompensated congestive heart failure, in which receiving 500ml of intrasvascular
             volume signifies a life risk.

          -  History of severe adverse events or anaphylaxis to plasma components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos A Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Infecciosas Francisco Javier Muniz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos A Gonzalez, MD</last_name>
    <phone>+54 9 1157233801</phone>
    <email>carlosgonzalez@buenosaires.gob.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Francisco Javier Muñiz</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>1663</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A Gonzalez, MD</last_name>
      <phone>+54 9 1157233801</phone>
      <email>carlosgonzalez@buenosaires.gob.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984 Aug 4;2(8397):255-6.</citation>
    <PMID>6146809</PMID>
  </reference>
  <reference>
    <citation>Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, Rojas-Villarraga A, Ramírez-Santana C, Díaz-Coronado JC, Manrique R, Mantilla RD, Shoenfeld Y, Anaya JM. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020 Jul;19(7):102554. doi: 10.1016/j.autrev.2020.102554. Epub 2020 May 5. Review.</citation>
    <PMID>32380316</PMID>
  </reference>
  <reference>
    <citation>Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.</citation>
    <PMID>32253318</PMID>
  </reference>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <reference>
    <citation>Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020 Jul;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039. Epub 2020 Mar 31.</citation>
    <PMID>32243945</PMID>
  </reference>
  <reference>
    <citation>Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J, Ahn MY, Chin BS, Kim YS, Lee H, Yong D, Kim HO, Kim S, Choi JY. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020 Apr 13;35(14):e149. doi: 10.3346/jkms.2020.35.e149.</citation>
    <PMID>32281317</PMID>
  </reference>
  <reference>
    <citation>Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.25882. [Epub ahead of print]</citation>
    <PMID>32293713</PMID>
  </reference>
  <reference>
    <citation>Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020 May 1. doi: 10.1002/jmv.25961. [Epub ahead of print] Review.</citation>
    <PMID>32356910</PMID>
  </reference>
  <reference>
    <citation>Joyner M, Wright RS, Fairweather D, Senefeld J, Bruno K, Klassen S, Carter R, Klompas A, Wiggins C, Shepherd JR, Rea R, Whelan E, Clayburn A, Spiegel M, Johnson P, Lesser E, Baker S, Larson K, Ripoll Sanz J, Andersen K, Hodge D, Kunze K, Buras M, Vogt M, Herasevich V, Dennis J, Regimbal R, Bauer P, Blair J, van Buskirk C, Winters J, Stubbs J, Paneth N, Casadevall A. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. medRxiv. 2020 May 14. pii: 2020.05.12.20099879. doi: 10.1101/2020.05.12.20099879. Update in: J Clin Invest. 2020 Aug 10;:.</citation>
    <PMID>32511566</PMID>
  </reference>
  <reference>
    <citation>Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 May 14;5:CD013600. doi: 10.1002/14651858.CD013600. Update in: Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600.</citation>
    <PMID>32406927</PMID>
  </reference>
  <reference>
    <citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. Review.</citation>
    <PMID>25030060</PMID>
  </reference>
  <reference>
    <citation>Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang QW, Xu SY, Zhu HD, Xu YC, Jin Q, Sharma L, Wang L, Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.</citation>
    <PMID>32198501</PMID>
  </reference>
  <reference>
    <citation>To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23.</citation>
    <PMID>32213337</PMID>
  </reference>
  <reference>
    <citation>Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010 Apr;38(4 Suppl):e66-73. doi: 10.1097/CCM.0b013e3181d44c1e. Review.</citation>
    <PMID>20154602</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003 Jun;9(3):199-201.</citation>
    <PMID>12777656</PMID>
  </reference>
  <reference>
    <citation>Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006 Dec;12(6):489.</citation>
    <PMID>17148811</PMID>
  </reference>
  <reference>
    <citation>Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion. 2010 Jun;50(6):1384-98. doi: 10.1111/j.1537-2995.2010.02590.x. Epub 2010 Feb 11. Review.</citation>
    <PMID>20158681</PMID>
  </reference>
  <reference>
    <citation>Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007 Oct 4;357(14):1450-1.</citation>
    <PMID>17914053</PMID>
  </reference>
  <reference>
    <citation>Wong HK, Lee CK, Hung IF, Leung JN, Hong J, Yuen KY, Lin CK. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010 Sep;50(9):1967-71. doi: 10.1111/j.1537-2995.2010.02651.x.</citation>
    <PMID>20412524</PMID>
  </reference>
  <reference>
    <citation>Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.</citation>
    <PMID>32113510</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <reference>
    <citation>Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev. 2020 Apr;34(2):75-80. doi: 10.1016/j.tmrv.2020.02.003. Epub 2020 Feb 21. Review.</citation>
    <PMID>32107119</PMID>
  </reference>
  <reference>
    <citation>Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011 Feb 15;52(4):447-56. doi: 10.1093/cid/ciq106. Epub 2011 Jan 19.</citation>
    <PMID>21248066</PMID>
  </reference>
  <reference>
    <citation>Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020 Apr 28;323(16):1561-1562. doi: 10.1001/jama.2020.4940.</citation>
    <PMID>32219429</PMID>
  </reference>
  <reference>
    <citation>Toy P. Update on transfusion-related acute lung injury. Clin Adv Hematol Oncol. 2019 Jul;17(7):378-381. Review.</citation>
    <PMID>31449502</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Infecciosas Francisco Javier Muniz</investigator_affiliation>
    <investigator_full_name>Carlos Alberto Gonzalez</investigator_full_name>
    <investigator_title>Blood Bank Director in Hospital de Infecciosas Francisco Javier Muniz</investigator_title>
  </responsible_party>
  <keyword>Convalescent plasma</keyword>
  <keyword>Covid-19 treatment</keyword>
  <keyword>Transfusion medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04468009/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04468009/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

